Biotech: Page
-
Getty Images
Astellas application rejected by FDA; Cytokinetics strikes licensing deal with Bayer
The agency turned back Astellas’ attempt to update its drug Izervay’s labeling. Elsewhere, former NCI director Ned Sharpless founded a new startup and Novartis licensed another radiopharma drug.
By BioPharma Dive staff • Nov. 19, 2024 -
Permission granted by Incyte
Incyte sinks on setback for drugs acquired in $750M buyout
The company paused testing of one candidate acquired in its April deal for Escient and scrapped another in a blow to its diversification plans.
By Ben Fidler • Nov. 19, 2024 -
Explore the Trendline➔
National Institutes of Allergy and Infectious Diseases. (2016). "Human natural killer cell" [Micrograph]. Retrieved from Flickr.
TrendlineCell therapy
The continued emergence of CAR-T therapy has fueled research into next-generation approaches and new applications, such as its use in autoimmune diseases or in reprogramming cells inside the body.
By BioPharma Dive staff -
Permission granted by Intellia Therapeutics
Gene editingCRISPR therapy from Intellia may ameliorate rare heart disorder, data suggest
Phase 1 data indicate Intellia’s medicine could be a powerful treatment for a cardiac form of ATTR amyloidosis. But rival drugs are further ahead.
By Ned Pagliarulo • Nov. 18, 2024 -
Getty Images
Q&A // Brain drug revivalHow a Biogen drug set the stage for a new biotech targeting ALS
Trace Neuroscience, which launched this week with $101 million, benefited from last year’s approval of Qalsody. Its CEO spoke with BioPharma Dive about how the company came together.
By Jacob Bell • Nov. 15, 2024 -
Joey Sirmons / BioPharma Dive/BioPharma Dive
‘Find any advantage’: 3 biotech leaders on driving R&D success
“Many companies just iterate indefinitely without ever making progress toward an actual drug,” said one biotech VC on a panel hosted by BioPharma Dive.
By Jonathan Gardner • Nov. 15, 2024 -
Joey Sirmons / BioPharma Dive/BioPharma Dive
Emerging biotechSurviving in biotech’s new normal: 5 tips from industry VCs and CEOs
At an event hosted by BioPharma Dive, drugmaker executives and investors discussed the importance of focus, smart spending and maintaining lines of sight to the clinic.
By Ned Pagliarulo , Delilah Alvarado • Nov. 15, 2024 -
Getty Images
Halozyme bids for Evotec; BeiGene gets a new name
The San Diego biotech made an unsolicited bid to buy Evotec for 2 billion euros. Elsewhere, Bluebird recorded its first Lyfgenia revenue and Leerink built up its M&A team.
By BioPharma Dive staff • Nov. 15, 2024 -
Courtesy of Eisai
New Alzheimer's drugsEisai wins over European regulators on Alzheimer’s drug Leqembi
The EMA sided against the drug this summer. But an appeal from Eisai appears to have worked, teeing Leqembi up for authorization in a major market.
By Jacob Bell • Nov. 14, 2024 -
Getty Images
Merck, facing threat to Keytruda, buys into new kind of cancer immunotherapy
The company is paying China-based biotech LaNova Medicines $588 million for the same type of bispecific antibody drug that recently bested Keytruda in a clinical trial.
By Ben Fidler • Nov. 14, 2024 -
Kimberly White/Getty Images via Getty Images
23andMe to lay off more than 200 employees amid business struggles
The genetic testing firm will also close its drug development arm. CEO Anne Wojcicki said the cuts are necessary to “focus on the long-term success of our core consumer business.”
By Ricky Zipp • Nov. 13, 2024 -
Getty Images
Amgen shares sink on obesity drug concerns; AstraZeneca to spend $3.5B on manufacturing
An analyst note raising questions about Amgen’s MariTide triggered a stock sell-off Tuesday. Elsewhere, Roche and Novartis struck drug discovery deals.
By BioPharma Dive staff • Nov. 13, 2024 -
Getty Images
Metsera raises $215M to accelerate obesity drug plans
With promising Phase 1 results in hand, Metsera hopes to develop a longer-lasting GLP-1 injection along with other types of obesity treatments.
By Kristin Jensen • Nov. 13, 2024 -
Permission granted by TRex Bio
TRex Bio raises $84M to compete in crowded immune drug field
The California biotech has drawn partnerships with Eli Lilly and J&J on the promise of its approach to rebalancing the immune system.
By Gwendolyn Wu • Nov. 13, 2024 -
Thomas Lohnes via Getty Images
BioNTech to buy Biotheus, gaining control of cancer bispecific
Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit Therapeutics’ ivonescimab.
By Jonathan Gardner • Nov. 13, 2024 -
Permission granted by Flagship Pioneering
GSK partners with Flagship startup to hunt for Parkinson’s drugs
Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for Parkinson’s and another neurodegenerative condition.
By Gwendolyn Wu • Nov. 12, 2024 -
Getty Images
Biotech investors, including Third Rock, pump $100M into a startup’s genetic medicine for ALS
Trace Neuroscience aims to advance an RNA-binding therapy designed to preserve — and potentially improve — muscle function in people living with the nerve-destroying disorder.
By Jacob Bell • Nov. 12, 2024 -
Getty Images
FDA approves new CAR-T competitor to Gilead’s Tecartus
Developer Autolus set a list price of $525,000 for its new cell therapy, which it will sell for a type of leukemia under the brand name Aucatzyl.
By Jonathan Gardner • Nov. 11, 2024 -
Sarah Silbiger via Getty Images
FDA lifts pause on Novavax flu vaccine trials
After an investigation, the agency concluded that a case of muscle weakness in one of Novavax’s trials was actually ALS and unrelated to vaccination.
By Delilah Alvarado • Nov. 11, 2024 -
Shutterstock/Ad_hominem
Sponsored by LabConnect7 steps to selecting the right global central lab
Unlock global clinical trial success with seamless sample logistics and standardized testing.
Nov. 11, 2024 -
Permission granted by Cullinan Therapeutics
Sponsored by Cullinan TherapeuticsFueling accelerated drug development in autoimmune diseases with a modality-agnostic approach
Innovation-without-borders philosophy seeks to bring forward only the most promising therapies.
By Cullinan Therapeutics • Nov. 11, 2024 -
Getty Images
Kalaris to go public via reverse merger with AlloVir
After Kalaris and AlloVir combine, the new company will have about $100 million to advance a treatment for age-related macular degeneration.
By Delilah Alvarado • Updated Nov. 8, 2024 -
Getty Images
Tezspire succeeds in chronic rhinosinusitis; Gilead writes down Trodelvy value
AstraZeneca and Amgen's drug could have a new use after positive Phase 3 study results. Elsewhere, Jazz set new plans for a narcolepsy drug and CDMO Avid Bioservices agreed to be taken private.
By BioPharma Dive staff • Nov. 8, 2024 -
Getty Images
Athira exploring strategic alternatives after Alzheimer’s failure
On the heels of its most advanced medicine flunking a key study, the drugmaker is looking at the different paths it could take to “maximizing stockholder value.”
By Jacob Bell • Nov. 8, 2024 -
Jacob Bell/BioPharma Dive
Moderna earnings beat forecasts, but analysts question whether sales spike will last
Sales of Moderna’s COVID-19 shot exceeded expectations, but the company’s launch of its new RSV vaccine has started slowly.
By Ned Pagliarulo • Nov. 7, 2024 -
Jacob Bell/BioPharma Dive
Sarepta scraps a Duchenne drug as gene therapy sales rise
Elevidys sales have increased since the FDA made a controversial choice to expand the therapy's use. Meanwhile, Sarepta is abandoning a successor to its drug Exondys 51, citing an “evolving" treatment landscape.
By Kristin Jensen • Nov. 7, 2024
Previous
